A major milestone for the P5 OPTIMAL trial: the first patients have now been randomized in the U.S.
P5 is exploring a new paradigm for the assessment and management of coronary calcium before complex PCI, using #CCTA to guide treatment planning and calcium modification strategies.
Congratulations to the Minneapolis Heart Institute @MHIF_Heart, @yadersandoval@ManosBR and team for becoming our first U.S. enrolling site and for being at the forefront of innovation and clinical care.
@jcspratt@crfheart@Heartflow@ShockwaveIVL@GEHealthCare#PCI#CoronaryCalcium#CardiacCT#CCTA
MHIF is the first activated U.S. enrolling site for this trial, evaluating whether coronary CT imaging can better guide treatment planning before complex PCI than intravascular ultrasound. The trial is led by Global PI @ColletCarlos of @crfheart: buff.ly/di8W4Bm
Great #innovation session to close out #NYValves2026. Possible novel treatment option for LVAD patients with AR but further study is ongoing and needed. @crfheart@TCTMD
What an informative session! We continue to learn from eachothers’ experience regarding patient selection- whom to treat remains a challenging decision sometimes. One size does not fit all and tailored approaches to individual patients are critical.
Excited regarding the upcoming LAAC summit at NY Valves! This will be packed with excellent sessions focused on the latest and greatest in this space for EPs and structuralists alike! @crfheart@TCTConference